Clinical Trial Update: Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating immunogenicity and reactogenicity of a meningococcal B outer membrane vesicle vaccine in a 0,6,12 month schedule in healthy UK a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neisseria Meningitidis Disease

Drugs mentioned

• Meningococcal B outer membrane vesicle vaccine

Snippet

Sponsor: Public Health England | Conditions: Neisseria Meningitidis | Phase 2 | Status: COMPLETED